Development aspects of gene therapy : Human somatic gene therapyPAVIRANI, A.Biologicals (Print). 1995, Vol 23, Num 1, issn 1045-1056, p.3Article

Genetic engineering of antihaemophilic factorsPAVIRANI, A; MEULIEN, P.Chimica oggi. 1988, Num 4, pp 41-45, issn 0392-839XArticle

Traitement de la mucoviscidose, transfert du gène CFTR à l'aide de vecteurs adénoviraux = Cystic fibrosis treatment with adenoviral-vector mediated CFTR gene transfertBELLON, G; PAVIRANI, A.Archives de pédiatrie (Paris). 1996, Vol 3, pp 82s-87s, issn 0929-693X, SUP1Conference Paper

Expression of human α₁-antitrypsin using a recombinant adenovirus vectorGILARDI, P; COURTNEY, M; PAVIRANI, A et al.FEBS letters. 1990, Vol 267, Num 1, pp 60-62, issn 0014-5793, 3 p.Article

Thérapie génique de la mucoviscidose par transfert adénoviral du gène CFTR = Gene therapy for cystic fibrosis using adenovirus vectorsPAVIRANI, A; SCHATZ, C; MEHTALI, M et al.MS. Médecine sciences. 1996, Vol 12, Num 1, pp 25-33, issn 0767-0974Article

USE OF TRYPANOSOMA EQUIPERDUM INFECTED RABBITS AS A SOURCE OF SPLENIC MRNA; CONSTRUCTION OF CDNA CLONES AND IDENTIFICATION OF A RABBIT MU HEAVY CHAIN CLONEBERNSTEIN KE; PAVIRANI A; ALEXANDER C et al.1983; MOLECULAR IMMUNOLOGY; ISSN 0161-5890; GBR; DA. 1983; VOL. 20; NO 1; PP. 89-99; BIBL. 2 P.Article

Peut-on guérir la mucoviscidose? = Can we treat cystic fibrosis?BELLON, G; PAVIRANI, A; LAMY, D et al.Recherche (Paris, 1970). 1994, Num 270, pp 1119-1121, issn 0029-5671Article

Essais cliniques de thérapie génique de la mucoviscidose : état des lieux et perspectives = Gene therapy for cystic fibrosis : present status and perspectivesPAVIRANI, A; REGULIER, E; BELLON, G et al.MS. Médecine sciences. 1999, Vol 15, Num 5, pp 595-605, issn 0767-0974Article

Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropismLEISSNER, P; LEGRAND, V; SCHLESINGER, Y et al.Gene therapy (Basingstoke). 2001, Vol 8, Num 1, pp 49-57, issn 0969-7128Article

Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx miceBRAUN, S; THIOUDELLET, C; PAVIRANI, A et al.Gene therapy (Basingstoke). 2000, Vol 7, Num 17, pp 1447-1457, issn 0969-7128Article

Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectorsIMLER, J.-L; CHARTIER, C; DREYER, D et al.Gene therapy (Basingstoke). 1996, Vol 3, Num 1, pp 75-84, issn 0969-7128Article

Thérapie génique de maladies infectieuses : le modèle du SIDA = Gene therapy for infectious diseases : the AIDS modelSORG, T; LEISSNER, P; CALENDA, V et al.MS. Médecine sciences. 1996, Vol 12, Num 1, pp 13-24, issn 0767-0974Article

Interaction of von Willebrand factor with platelets activated by thrombin or a synthetic 7-amino acid peptide derived from the cleaved thrombin receptorMINCKES, O; FREYSSINET, J.-M; ROUAULT, C et al.Comptes rendus de l'Académie des sciences. Série 3, Sciences de la vie. 1994, Vol 317, Num 4, pp 363-370, issn 0764-4469Article

Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutationDALEMANS, W; BARBRY, P; CHAMPIGNY, G et al.Nature (London). 1991, Vol 354, Num 6354, pp 526-528, issn 0028-0836Article

Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial originYOSHIMURA, K; NAKAMURA, H; TRAPNELL, B. C et al.Nucleic acids research. 1991, Vol 19, Num 19, pp 5417-5423, issn 0305-1048Article

In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epitheliumROSENFELD, M. A; YOSHIMURA, K; PERRICAUDET, M et al.Cell (Cambridge). 1991, Vol 68, Num 1, pp 143-155, issn 0092-8674Article

A Taq I polymorphism in the 5' region of the von Willebrand factor (vWF) geneLAVERGNE, J. M; BAHNAK, B. R; ASSOULINE, Z et al.Nucleic acids research. 1988, Vol 16, Num 6, issn 0305-1048, 2742Article

Effect of liposome-encapsulated clodronate pretreatment on synthetic vector-mediated gene expression in miceSCHUGHART, K; BISCHOFF, R; HADJI, D. A et al.Gene therapy (Basingstoke). 1999, Vol 6, Num 3, pp 448-453, issn 0969-7128Article

Successful expression of β-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical veinTHEMIS, M; SCHNEIDER, H; COUTELLE, C et al.Gene therapy (Basingstoke). 1999, Vol 6, Num 7, pp 1239-1248, issn 0969-7128Article

A method for the rapid detection of recombinant CFTR during gene therapy in cystic fibrosisDEMOLOMBE, S; BARO, I; BEBOK, Z et al.Gene therapy (Basingstoke). 1996, Vol 3, Num 8, pp 685-694, issn 0969-7128Article

La thérapie génique dans la mucoviscidose = Gene therapy for cystic fibrosis SCHATZ, C; PAVIRANI, A.Revue de pneumologie clinique (Paris). 1995, Vol 51, Num 3, pp 201-206, issn 0761-8417Article

Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transferMASTRANGELI, A; DANEL, C; ROSENFELD, M. A et al.The Journal of clinical investigation. 1993, Vol 91, Num 1, pp 225-234, issn 0021-9738Article

Hydrophobic cluster analysis of G protein-coupled receptors : a powerful tool to derive structural and functional information from 2D-representation of protein sequencesLENTES, K.-U; MATHIEU, E; BISCHOFF, R et al.Journal of receptor research. 1993, Vol 13, Num 1-4, pp 179-194, issn 0197-5110Conference Paper

Characterization of recombinant human factor IX expressed in transgenic mice and in derived transgenic mice and in derived transimmortalized hepatic cell linesJALLAT, S; PERRAUD, F; DALEMANS, W et al.EMBO journal (Print). 1990, Vol 9, Num 10, pp 3295-3301, issn 0261-4189, 7 p.Article

Heterologous protein expression by transimmortalized differentiated liver cell lines derived from transgenic mice (hepatomas/α₁ hantitrypsin/ONC mouse)DALEMANS, W; PERRAUD, F; LE MEUR, M et al.Biologicals (Print). 1990, Vol 18, Num 3, pp 191-198, issn 1045-1056, 8 p.Article